Having trouble accessing articles? Reset your cache.

Alphamab Oncology sets sights on $220M IPO as HKSE continues to gain momentum

Alphamab Oncology is aiming to raise about HK$1.7 billion ($221.1 million) in an IPO on the Hong Kong stock exchange next week in an offering that would value the company at HK$8.7 billion if priced at the midpoint of the proposed range.

The pre-profit company proposed to sell 179.4 million shares at HK$9.10-HK$10.20 on the exchange’s biotech chapter.

The announcement came on the heels of an IPO on the exchange by Pharmaron Beijing

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE